AMICUS THERAPEUTICS, INC.FOLDEarnings & Financial Report

Nasdaq · pharmaceutical industry

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

NextMar 13, 2026

Revenue

$169.1M

Gross Profit

$149.6M

Operating Profit

$34.3M

Net Profit

$17.3M

Gross Margin

88.5%

Operating Margin

20.3%

Net Margin

10.2%

YoY Growth

19.5%

EPS

$0.06

Financial Flow

AMICUS THERAPEUTICS, INC. Q3 2025 Financial Summary

AMICUS THERAPEUTICS, INC. reported revenue of $169.1M for Q3 2025, with a net profit of $17.3M (10.2% margin). Cost of goods sold was $19.5M, operating expenses totaled $115.3M.

Key Financial Metrics

Total Revenue	$169.1M
Net Profit	$17.3M
Gross Margin	88.5%
Operating Margin	20.3%
Report Period	Q3 2025

AMICUS THERAPEUTICS, INC. Annual Revenue by Year

AMICUS THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $528.3M).

Year	Annual Revenue
2024	$528.3M
2023	$399.4M
2022	$329.2M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$115.1M	$110.4M	$126.7M	$141.5M	$149.7M	$125.2M	$154.7M	$169.1M
YoY Growth	30.6%	28.0%	34.0%	36.7%	30.1%	13.4%	22.1%	19.5%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$777.9M	$721.8M	$749.5M	$786.6M	$785.0M	$789.8M	$815.3M	$868.8M
Liabilities	$617.7M	$591.1M	$617.0M	$607.7M	$591.0M	$596.3M	$611.0M	$638.4M
Equity	$160.2M	$130.7M	$132.5M	$178.8M	$194.0M	$193.6M	$204.3M	$230.4M